Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 8/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10897393 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL10897931 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL17287183 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL10897385 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL18332762 | 0.94 | CYP3A4 (0.55) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24238614 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24806634 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL13785420 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24824205 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL21730994 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-2231195-B1 | TARGETING LIPIDS | ARBUTUS BIOPHARMA CORP (CA) | 2017-03-29 | — | — | EP | disclosed |
| EP-3141265-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | CYP3A4 4857/4885MAPT 4586/4885CYP2C9 4833/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | CYP3A4 4211/4885MAPT 4545/4885CYP2C9 4162/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | CYP3A4 4579/4885MAPT 4153/4885CYP2C9 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.